HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: AJPH.2004.057810v1 96/7/1308    most recent Submit a response View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Stokley, S. Articles by Shefer, A. Search for Related Content PubMed PubMed Citation Articles by Stokley, S. Articles by Shefer, A. Related Collections Other Health Financing Immunization/Vaccines

Shannon Stokley, MPH, Kate M. Shaw, MS, Lawrence Barker, PhD, Jeanne M. Santoli, MD, MPH and Abigail Shefer, MD

At the time of the study, all of the authors were with the National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Ga.

Correspondence: Requests for reprints should be sent to Shannon Stokley, MPH, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mail Stop E-52, Atlanta, GA 30333 (e-mail: sstokley{at}cdc.gov).

Objective. We examined heptavalent pneumococcal conjugate vaccine (PCV7) uptake among children aged 19 to 35 months in the United States and determined how uptake rates differed by state vaccine financing policy.

Methods. We analyzed data from the 2001–2003 National Immunization Survey. States that changed their vaccine financing policy between 2001 and 2003 (n=17) were excluded from analysis. Logistic regression was performed to identify the association between state vaccine financing policy and receipt of 3 or more doses of PCV7 after control for demographic characteristics.

Results. The proportion of children receiving 3 or more doses increased from 6.7% in 2001 to 69.0% in 2003. After controlling for demographic characteristics, children residing in states that provided all vaccines except PCV7 to all children had lower odds of receiving 3 or more doses compared to children residing in states that provided PCV7 only to children eligible for the Vaccines for Children program (odds ratio=0.58; 95% confidence interval=0.51, 0.66).

Conclusion. It is essential that we continue to monitor the effect that state vaccine financing policy has on the delivery of PCV7 and future vaccines, which are likely to be increasingly expensive.

This article has been cited by other articles:

				C. A. Gidengil, D. Rusinak, N. J. Allred, D. Luff, G. M. Lee, and T. A. Lieu Financial Barriers to Implementing Combination Vaccines: Perspectives From Pediatricians and Policy Makers Clinical Pediatrics, June 1, 2009; 48(5): 539 - 547. [Abstract] [PDF]

				G. M. Lee, J. M. Santoli, C. Hannan, M. L. Messonnier, J. E. Sabin, D. Rusinak, C. Gay, S. M. Lett, and T. A. Lieu Gaps in Vaccine Financing for Underinsured Children in the United States JAMA, August 8, 2007; 298(6): 638 - 643. [Abstract] [Full Text] [PDF]